These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 37037286

  • 1. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
    Singh AK, Singh A, Singh R.
    Endocr Pract; 2023 Jul; 29(7):509-516. PubMed ID: 37037286
    [Abstract] [Full Text] [Related]

  • 2. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL, Halvorson AE, Hackstadt AJ, Hung AM, Greevy R, Grijalva CG, Elasy TA, Roumie CL.
    Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
    [Abstract] [Full Text] [Related]

  • 3. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.
    Chan YH, Chao TF, Chen SW, Kao YW, Huang CY, Chu PH.
    Eur Heart J Qual Care Clin Outcomes; 2023 Jun 21; 9(4):397-407. PubMed ID: 35797996
    [Abstract] [Full Text] [Related]

  • 4. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Providencia R, Kwong JS.
    Cochrane Database Syst Rev; 2021 Oct 25; 10(10):CD013650. PubMed ID: 34693515
    [Abstract] [Full Text] [Related]

  • 5. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY, Yang CT, Kuo S, Wu CH, Lin WH, Ou HT.
    JAMA Netw Open; 2022 Dec 01; 5(12):e2246928. PubMed ID: 36520437
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS, Lee JK, Hung CS, Chen WJ.
    Diabetologia; 2021 Dec 01; 64(12):2676-2686. PubMed ID: 34536085
    [Abstract] [Full Text] [Related]

  • 7. Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
    Kashiwagi A, Shoji S, Onozawa S, Kosakai Y, Waratani M, Ito Y.
    J Diabetes Investig; 2022 Jul 01; 13(7):1175-1189. PubMed ID: 35243799
    [Abstract] [Full Text] [Related]

  • 8. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X, Zhang N, Lu L, Gao T, Chou OHI, Wong WT, Chang C, Wai AKC, Lip GYH, Zhang Q, Tse G, Liu T, Zhou J.
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb 23; 10(2):103-117. PubMed ID: 37962962
    [Abstract] [Full Text] [Related]

  • 9. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, Liu T, Wong WT, Chang C, Wong ICK, Cheung BMY, Tse G, Zhang Q.
    Cardiovasc Drugs Ther; 2023 Jun 23; 37(3):561-569. PubMed ID: 35142921
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J, Bates BA, Setoguchi S, Gerhard T, Dave CV.
    Cardiovasc Diabetol; 2023 Mar 10; 22(1):54. PubMed ID: 36899387
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chiang FT, Tu YK.
    Eur J Endocrinol; 2023 Jul 20; 189(1):S17-S25. PubMed ID: 37474112
    [Abstract] [Full Text] [Related]

  • 12. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, Esposito K.
    Cardiovasc Diabetol; 2022 Mar 16; 21(1):42. PubMed ID: 35296336
    [Abstract] [Full Text] [Related]

  • 13. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J, Lee S, Leung KSK, Wai AKC, Liu T, Liu Y, Chang D, Wong WT, Wong ICK, Cheung BMY, Zhang Q, Tse G.
    ESC Heart Fail; 2022 Apr 16; 9(2):1388-1399. PubMed ID: 35132823
    [Abstract] [Full Text] [Related]

  • 14. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
    Kashiwagi A, Shoji S, Kosakai Y, Koga T, Asakawa K, Rokuda M.
    J Diabetes Investig; 2023 Mar 16; 14(3):404-416. PubMed ID: 36515129
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK, Kang YM, Lee SE, Lee J, Park JY, Lee WJ, Kim YJ, Jung CH.
    Diabetes Metab; 2018 Nov 16; 44(5):393-401. PubMed ID: 29449146
    [Abstract] [Full Text] [Related]

  • 16. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K, Giugliano D.
    Cardiovasc Diabetol; 2021 Oct 18; 20(1):210. PubMed ID: 34663316
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium-glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors.
    Lee HF, Chan YH, Chuang C, Li PR, Yeh YH, Hsiao FC, Peng JR, See LC.
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun 02; 9(4):301-310. PubMed ID: 36639127
    [Abstract] [Full Text] [Related]

  • 18. Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.
    Qiu M, Zhou X, Zhang M.
    Diabetes Obes Metab; 2022 Mar 02; 24(3):575-577. PubMed ID: 34729884
    [No Abstract] [Full Text] [Related]

  • 19. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK, Singh R.
    Diabetes Metab Syndr; 2021 Mar 02; 15(1):351-359. PubMed ID: 33503584
    [Abstract] [Full Text] [Related]

  • 20. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
    Lyu B, Grams ME, Chang A, Inker LA, Coresh J, Shin JI.
    Am J Cardiol; 2022 Feb 15; 165():124-130. PubMed ID: 34937658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.